Sofosbuvir/ledipasvir in combination or nitazoxanide alone are safe and efficient treatments for COVID-19 infection: A randomized controlled trial for repurposing antivirals

Mohammed A. Medhat; Mohamed El-Kassas; Haidi Karam-Allah; Ahmed Al Shafie; Sherief Abd-Elsalam; Ehab Moustafa; Sahar M. Hassany; Marwa Salama; Mohamed S. Abd Elghafar; Hamdy Sayed; Mohamed Badr; Dalia T. Kamal; Ahmed Shamseldeen; Ashima'a Ossimi; Inas Moaz; Hossam El-deen Esmael; Azza M. Ezz Eldin; Sameera Ezzat; Hossam Abdelghaffar; Khaled Abdelghaffar

doi:10.1016/j.ajg.2022.04.005

Citations

392

Views

Abstract not available for this publication.

Cite this Article (APA)

Mohammed, A. M., Mohamed, E., Haidi, K., Ahmed, A. S., Sherief, A., Ehab, M., Sahar, M. H., Marwa, S., Mohamed, S. A. E., Hamdy, S., Mohamed, B., Dalia, T. K., Ahmed, S., Ashima'a, O., Inas, M., Hossam, E. E., Azza, M. E. E., Sameera, E., Hossam, A., Khaled, A. (2022). Sofosbuvir/ledipasvir in combination or nitazoxanide alone are safe and efficient treatments for COVID-19 infection: A randomized controlled trial for repurposing antivirals. Arab Journal of Gastroenterology. https://doi.org/10.1016/j.ajg.2022.04.005